Start:
December 2015
End:
November 2017
Enrollment:
20
This Phase II study will test safety and efficacy of the experimental drug nelotanserin for the treatment of visual hallucinations in people with Lewy body dementia.
Minimum Age: 50 Years
Maximum Age: 85 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Who Is the General Study Contact?
For more information about this clinical trial, please contact Axovant Clinical Trials at 919-425-0709 or visit www.lbda.org/nelotanserin-VH.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: Axovant Sciences Ltd.
Source: ClinicalTrials.gov ID: NCT02640729
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health